Newron completes screening for ENIGMA-TRS 1 Phase 3 enrollment
Newron Pharmaceuticals said it has completed screening for enrollment in its pivotal Phase 3 ENIGMA-TRS 1 study. Evenamide will be used as add-on therapy in patients with treatment-resistant schizophrenia.